Characteristics of groups and results of screening assessment
| T Spot | Quantiferon | |
|---|---|---|
| Number of subjects | 90 | 82 |
| Median Age [years], (range) | 35 (17–70) | 35 (17–76) |
| Risk Factors for TB | 12% | 16% |
| On immunomodulators | 63/90 (70%) | 66/82 (80%) |
| Pos IGRA | 0 | 3 |
| Neg IGRA | 61 | 52 |
| Borderline IGRA | 1 | 2 |
| Indeterminate IGRA | 1 | 9 |
| No immodulators | 27/90 (30%) | 16/82 (20%) |
| Pos IGRA | 2 | 0 |
| Neg IGRA | 22 | 15 |
| Borderline IGRA | 0 | 0 |
| Indeterminate IGRA | 3 | 1 |
| Cost/assay | £60.00 | £35.00 |
| Cost/patient assessment | £66.13 | £52.41 |
| Median follow up | 29 months | 13 months |